Table 1. Baseline characteristics of 183 participants.
| Variable | Mean (±SD) or number (%) |
| Age (years) | 55± 15 |
| Male | 105(57%) |
| Diabetes mellitus | 52(28%) |
| Hypertension | 165(90%) |
| Smoking (current or former) | 92(51%) |
| Hypercholesterolemia | 98(54%) |
| Previous cardiovascular events | 82(45%) |
| Body mass index (BMI) (kg/m2) | 27±5 |
| Blood Pressure (BP) | |
| Systolic BP (mmHg) | 145±22 |
| Diastolic BP (mmHg) | 82±13 |
| Causes of renal disease | |
| Diabetic nephropathy | 41(22%) |
| Chronic GN | 44(24%) |
| Renovascular /hypertensive nephrosclerosis | 15(8%) |
| Reflux nephropathy | 12(7%) |
| Adult Polycystic Kidney Disease (ADPKD) | 18(10%) |
| Others | 34(19%) |
| Unknown | 19(10%) |
| Renal factors | |
| Stage 4/5 CKD (GFR<30ml/min) | 68(37%) |
| Hemodialysis | 73(40%) |
| Peritoneal Dialysis | 42(23%) |
| Duration of dialysis (y)(median and IQR) | 1.8(0.5–4.0) |
| Received Renal Transplant | 70(38%) |
| Biochemistry | |
| Corrected Calcium (mmol/L) | 2.4±0.2 |
| Phosphate (mmol/L) | 1.8±0.5 |
| Parathyroid Hormone (pmol/L) (median and IQR) | 30(14.5–59) |
| Albumin(g/L) | 38±5.2 |
| Hemoglobin(g/L) | 109±15 |
| Medication | |
| ACE inhibitor | 73(40%) |
| Β —Blocker | 60(33%) |
| Calcium channel blocker | 85(46%) |
| Cholesterol lowering agent | 102(56%) |
| Echocardiographic characteristics | |
| LV end diastolic volume (mm) | 140± 48 |
| LV end systolic volume (mm) | 79±37 |
| LV mass index (g/m2.7) | 55±17 |
| LV hypertrophy (LVMI > 51 g/m2.7) | 87(53%) |
| LV meridional systolic wall stress (dynes/cm2x1000) | 149.8 ± 48.5 |
| Ejection Fraction (%) | 45±11 |
| Global Longitudinal Strain (%) | -13.6±4.3 |
SD = standard deviation; CKD = chronic kidney disease; LV = left ventricular; LVMI = left ventricular mass index; GN = glomerulonephritis; ACE = angiotensin converting enzyme